AUS
NZ
UK
CA
USA
IND
Epiminder Limited (ASX:EPI), a Melbourne-based medical device company specialising in epilepsy monitoring technology, has announced the enrollment of its 50th patient in the DETECT clinical trial, achieving this milestone ahead of the initially projected mid-Q3 CY2026 deadline. This progress follows the 25th patient enrollment reported on 1 June 2026, indicating accelerated recruitment across the company’s expanding network of 20 active clinical sites in the United States. This development is a key indicator for investors monitoring Epiminder’s objective to enroll 210 patients in DETECT by the end of the first half of CY2027, a goal the company confirms remains on track.
Key Points
- Epiminder Limited (ASX:EPI) is an innovative medical device firm developing advanced epilepsy monitoring solutions, headquartered in Melbourne, Australia, with offices in the US.
- The 50th patient enrollment in the DETECT study was reached ahead of the mid-Q3 CY2026 target, following the 25th enrollment announced on 1 June 2026.
- Enrollment is active at 20 leading US clinical sites, including Mayo Clinic, Harvard, Stanford, Yale, Duke, and the University of Pennsylvania.
- Epiminder remains on schedule to enroll 210 patients in DETECT by the end of 1H CY2027, with an investor webinar planned for 9:30am AEST on Thursday, 30 July 2026.
Overview of Epiminder's DETECT Study Evaluating the FDA-Approved Minder System
The DETECT study (Diagnosing Epilepsy To EffeCT change) is a prospective, randomised, controlled, blinded, multi-centre clinical trial in the US designed to enroll up to 210 participants across as many as 25 sites. It assesses the Minder System’s effectiveness in improving clinical decisions for epilepsy patients who receive inconclusive results after prolonged inpatient electroencephalographic (EEG) monitoring. The study includes a six-month primary follow-up period, with its main endpoint being the percentage of participants who achieve an actionable clinical event such as confirmed diagnosis, seizure characterization, surgical evaluation, event classification, or psychogenic nonepileptic seizure determination.
Significantly, the Minder System is deployed in DETECT as a marketed device in a post-market study, having received US Food and Drug Administration authorization through the de novo pathway. The UMPIRE first-in-human multicentre trial, published in the peer-reviewed journal Epilepsia in 2025, demonstrated Minder’s safety and superior signal acquisition during extended monitoring. DETECT builds on this foundation with a larger scale and rigorous randomised controlled design to generate data that can influence clinical practice and reimbursement decisions.
Addressing the Diagnostic Gap in Drug-Resistant Epilepsy with the Minder System
The clinical rationale for DETECT is based on a significant diagnostic gap in epilepsy management. Epiminder’s update highlights that 30% to 50% of inpatient epilepsy monitoring unit stays yield inconclusive results, leaving approximately 25,000 to 45,000 patients annually in the US without confirmed diagnosis or clear treatment pathways. The inability to capture and characterize seizure events during short inpatient monitoring delays or prevents access to advanced treatments, including epilepsy surgery, a highly effective intervention for drug-resistant epilepsy.
The Minder System addresses this gap by enabling extended, continuous bilateral subscalp EEG monitoring during patients’ normal daily activities. Unlike inpatient monitoring limited by hospital stay durations, Minder records brain electrical activity continuously over months or years. Data is transmitted via an external wearable and smartphone app to a secure cloud platform, offering clinicians a comprehensive and long-term view of brain activity. The company notes that increasing site engagement across DETECT reflects growing clinician confidence in Minder’s ability to meet this unmet diagnostic need.
Enrollment Acceleration from 25 to 50 Patients and Its Implications for Epiminder’s Clinical Timeline
The rapid progression from 25 to 50 enrolled patients, achieved weeks ahead of the mid-Q3 CY2026 target, signals strong momentum within Epiminder’s clinical network. This doubling of enrollment in a short period reflects accelerating recruitment efforts across DETECT sites.
CEO Rohan Hoare stated that reaching 50 patients shortly after 25 demonstrates the growing engagement of clinical sites and their patient populations, underscoring the unmet clinical need Minder aims to address. The company remains confident in meeting the 210-patient enrollment goal by the end of the first half of CY2027. Investors and analysts may view this early milestone as a positive sign of Epiminder’s ability to achieve its recruitment targets, though final enrollment completion and primary endpoint data availability remain critical future milestones.
Twenty Prestigious US Clinical Sites Actively Enrolling in the DETECT Study
A standout feature of the DETECT study is the participation of 20 leading US clinical institutions actively enrolling patients. These include the Mayo Clinic, Harvard, Stanford, Yale, Duke, and the University of Pennsylvania, among the world’s foremost epilepsy research and treatment centers.
The involvement of these elite academic centers signifies institutional confidence in the Minder System and the scientific objectives of DETECT. Professor Mark Cook, Epiminder’s founder and Professor of Medicine at the University of Melbourne, noted that clinicians at these top epilepsy centers have adopted Minder for their patients, highlighting the clinical value of long-term continuous monitoring. The DETECT trial is registered on ClinicalTrials.gov under identifier NCT07110337, providing public verification of its design and scope.
Leadership Perspectives on the 50-Patient Enrollment Milestone
Epiminder’s CEO Rohan Hoare and founder Professor Mark Cook both commented on the milestone in the company update. Hoare described the 50th enrollment as a significant achievement reflecting strong momentum and site engagement, emphasizing the unmet need Minder addresses and reaffirming confidence in reaching 210 enrollments by mid-2027.
Professor Cook emphasized the human impact of each enrollment, noting that every patient enrolled lacked clear answers from conventional EEG monitoring. He highlighted DETECT’s role in generating meaningful evidence through its scale and site participation, and stressed Minder’s design to provide clinicians with extended brain activity monitoring during daily life, capturing events missed in short inpatient stays. Their statements collectively underscore clinical progress, institutional validation, and the broader medical importance of DETECT.
Functionality and Australian Research Origins of the Minder System
The Minder System is a minimally invasive implantable continuous EEG monitoring device, trademarked as iCEM by Epiminder. It records bilateral subscalp EEG data continuously and transmits it via an external wearable and smartphone app to a secure cloud platform. This allows patients to be monitored during normal daily activities over months or years, contrasting with conventional inpatient EEG monitoring limited to days or weeks.
Founded in 2017 by Professor Mark Cook alongside the Bionics Institute, St Vincent's Hospital, the University of Melbourne, and Cochlear Limited, Epiminder is a consortium of leading Australian medical research and commercialisation institutions. The company focuses on developing diagnostic and treatment tools for epilepsy and seizure disorders requiring continuous monitoring. Headquartered in Melbourne with US offices, Epiminder combines Australian R&D with US clinical commercialization. It listed on the ASX in December 2025.
Upcoming Investor Webinar to Review Progress Since December 2025 IPO
Coinciding with the 50-patient milestone, Epiminder announced an investor webinar scheduled for 9:30am AEST on Thursday, 30 July 2026. The webinar will update investors on progress since the company’s December 2025 IPO, marking the first public opportunity for direct engagement with its investor base regarding clinical, operational, and strategic developments.
Registration is open via a Zoom link provided in the company update, with confirmation emails sent to participants. Investors interested in DETECT enrollment trends, plans to reach the 25-site target, financial updates, and upcoming milestones may find this webinar particularly informative. The company has not detailed the agenda or whether investor Q&A will be included beyond confirming the date, time, and registration process.
Developmental Risks and Challenges on the Path to 210 DETECT Enrollments
As a clinical-stage medical device company, Epiminder’s near-term success heavily depends on the DETECT study’s execution. Although enrollment has exceeded initial expectations, achieving the full 210-patient goal by end of 1H CY2027 requires sustained site engagement and potentially activating additional sites to reach the study’s upper limit of 25. Any delays in site activation, recruitment pace, or regulatory changes could impact the timeline.
Furthermore, the six-month primary follow-up period means primary endpoint data will not be immediately available after full enrollment. The company has not disclosed anticipated timing for top-line data release or subsequent regulatory or commercial actions following positive outcomes. Having listed on the ASX only in December 2025, Epiminder remains early in its public market journey, with its future reliant on robust clinical evidence from DETECT and securing sufficient funding through data readout and beyond.
